Tweet
J Infect Dis. 2017 Nov 14. doi: 10.1093/infdis/jix594. [Epub ahead of print]
Intranasal Immunization with an Attenuated Pep27 Mutant Provides Protection from Influenza Virus and Secondary Pneumococcal Infections.
Seon SH1, Choi JA2, Yang E2, Pyo S1, Song MK2, Rhee DK1.
Author information
Abstract
During influenza pandemics, secondary pneumococcal infections cause excessive mortality. However, the current pneumococcal polysaccharide conjugate vaccine, PCV 13, provides only limited protection against secondary infection. Therefore, a more effective pneumococcal vaccine is required to protect against secondary pneumococcal infections. Here, intranasal immunization with an attenuated pneumococcal pep27 mutant provides protection from influenza virus infection, and also from secondary pneumococcal challenge. These results indicate that mucosal immunity might be an effective way to reduce the morbidity and mortality due to secondary pneumococcal infections during influenza pandemics.
? The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
Streptococcus pneumoniae; influenza A virus; whole cell vaccine
PMID: 29145619 DOI: 10.1093/infdis/jix594
Intranasal Immunization with an Attenuated Pep27 Mutant Provides Protection from Influenza Virus and Secondary Pneumococcal Infections.
Seon SH1, Choi JA2, Yang E2, Pyo S1, Song MK2, Rhee DK1.
Author information
Abstract
During influenza pandemics, secondary pneumococcal infections cause excessive mortality. However, the current pneumococcal polysaccharide conjugate vaccine, PCV 13, provides only limited protection against secondary infection. Therefore, a more effective pneumococcal vaccine is required to protect against secondary pneumococcal infections. Here, intranasal immunization with an attenuated pneumococcal pep27 mutant provides protection from influenza virus infection, and also from secondary pneumococcal challenge. These results indicate that mucosal immunity might be an effective way to reduce the morbidity and mortality due to secondary pneumococcal infections during influenza pandemics.
? The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
Streptococcus pneumoniae; influenza A virus; whole cell vaccine
PMID: 29145619 DOI: 10.1093/infdis/jix594